Get the Stockscreener App
54.40
2.26%
-1.26
After Hours:
53.80
-0.60
-1.10%
Grail Inc stock is traded at $54.40, with a volume of 720.09K.
It is down -2.26% in the last 24 hours and down -1.07% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$55.66
Open:
$56.29
24h Volume:
720.09K
Relative Volume:
0.61
Market Cap:
$2.33B
Revenue:
$147.17M
Net Income/Loss:
$-408.35M
P/E Ratio:
-4.8664
EPS:
-11.1787
Net Cash Flow:
$-299.92M
1W Performance:
+4.21%
1M Performance:
-1.07%
6M Performance:
-35.73%
1Y Performance:
+58.79%
1-Day Range:
$54.03
$56.89
1-Week Range:
$49.15
$56.89
52-Week Range:
$29.95
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
54.40 | 2.39B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Mizuho | Neutral |
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
GRAIL Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Grail Q1 2026 revenue beats forecast, stock rises - Investing.com
GRAIL Inc. (GRAL) stock falls on Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (GRAL) GRAIL, Inc. Reports Q1 Revenue $40.8M, vs. FactSet Est of $39.2M - marketscreener.com
GRAIL (NASDAQ: GRAL) posts 28% Q1 growth and advances Galleri PMA - Stock Titan
GRAIL Reports First Quarter 2026 Financial Results - PR Newswire
Grail earnings ahead as investors weigh trial results, FDA path By Investing.com - Investing.com UK
GRAIL, Inc. Hits Day High with Strong 7.44% Intraday Surge - Markets Mojo
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill
GRAIL to Present at the BofA Securities 2026 Health Care Conference - ChartMill
Why Grail Stock Is Breaking Out Today - TipRanks
GRAIL announces leadership transition - MSN
GRAIL (GRAL) Price Target Decreased by 18.81% to 69.07 - MSN
GRAIL (NASDAQ: GRAL) outlines CEO transition, director elections in 2026 proxy - Stock Titan
GRAIL (GRAL) to Release Quarterly Earnings on Tuesday - MarketBeat
GRAIL rated new Neural at Mizuho and Piper after study setback - MSN
Grail posts latest trial data for Galleri cancer detection test - MSN
GRAL Technical Analysis | Trend, Signals & Chart Patterns | GRAIL INC (NASDAQ:GRAL) - ChartMill
GRAIL (GRAL) Price Target Decreased by 10.52% to 85.07 - MSN
Hims latest offering, Grail's Galleri cancer test, fails U.K. study - MSN
GRAIL and athenahealth partner to simplify ordering of cancer detection test - MSN
GRAL SEC FilingsGrail Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Trading the Move, Not the Narrative: (GRAL) Edition - Stock Traders Daily
Why GRAIL Inc Shares Are Surging Again Now - TipRanks
UBS AG (AMUB) sells $575K autocallable notes tied to GRAIL (GRAL) stock - Stock Titan
Grail partnering with Superpower to offer Galleri cancer early detection test - MSN
Grail, Epic plan Galleri test integration for 450 health systems - MSN
GRAL (GRAIL Inc.) posts narrower Q4 2025 loss and 17.2 percent revenue growth, shares dip 1.39 percent today.Guidance Update - Cổng thông tin điện tử tỉnh Tây Ninh
Bronstein, Gewirtz & Grossman, LLC Is Investigating GRAIL, Inc. (GRAL) And Encourages Shareholders to Connect - The National Law Review
GRAIL to Announce First Quarter 2026 Financial Results - marketscreener.com
GRAIL schedules May 5 webcast after Q1 results release - Stock Titan
GRAIL, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
GRAIL to present NHS-Galleri, PATHFINDER 2 data at ASCO meeting - Investing.com Australia
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting - GuruFocus
GRAIL to present NHS-Galleri, PATHFINDER 2 data at ASCO meeting By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GRAIL, Inc. (GRAL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GRAIL, Inc. (GRAL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
GRAIL partners with Epic to broaden Galleri test access across US - MSN
GRAIL, Inc. (GRAL) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
GRAIL, Inc. (GRAL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
Why Is GRAL Stock Rising Today? - MSN
GRAIL (GRAL) director Steven Mizell takes $19.7K in deferred stock units - Stock Titan
GRAIL (GRAL) director receives 408 deferred stock units as fees - Stock Titan
GRAIL (GRAL) director takes $31.4K in stock units instead of cash fees - Stock Titan
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):